CANCER CYTOPATHOLOGY

metrics 2024

Fostering Innovations in Cancer Research and Treatment

Introduction

Cancer Cytopathology, published by Wiley, is an esteemed journal that plays a pivotal role in the fields of Cancer Research and Oncology. With a focus on the microscopic examination and analysis of cancerous cells, this journal serves as a crucial platform for disseminating high-quality research aimed at improving diagnostic techniques and therapeutic strategies. The journal holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, emphasizing its influence and importance within the scientific community. Additionally, it is recognized in the top 76th percentile in Medicine - Oncology and the 63rd percentile in Cancer Research according to Scopus rankings. Operating from the United States, Cancer Cytopathology is dedicated to fostering cutting-edge research and exploration in cytopathology, providing essential insights into cancer progression and management. Researchers and practitioners alike will find this journal invaluable for staying on the forefront of advancements in cancer diagnostics.

Metrics 2024

SCIMAGO Journal Rank0.99
Journal Impact Factor2.60
Journal Impact Factor (5 years)3.10
H-Index68
Journal IF Without Self2.60
Eigen Factor0.00
Normal Eigen Factor0.63
Influence0.82
Immediacy Index0.70
Cited Half Life6.40
Citing Half Life5.80
JCI0.82
Total Documents1589
WOS Total Citations2930
SCIMAGO Total Citations12856
SCIMAGO SELF Citations1632
Scopus Journal Rank0.99
Cites / Document (2 Years)2.53
Cites / Document (3 Years)2.67
Cites / Document (4 Years)2.64

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #96/404
Percentile 76.24
Quartile Q1
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #84/230
Percentile 63.48
Quartile Q2

IF (Web Of Science)

ONCOLOGY
Rank 175/322
Percentile 45.80
Quartile Q3
PATHOLOGY
Rank 35/88
Percentile 60.80
Quartile Q2

JCI (Web Of Science)

ONCOLOGY
Rank 109/322
Percentile 66.15
Quartile Q2
PATHOLOGY
Rank 36/88
Percentile 59.09
Quartile Q2

Quartile History

Similar Journals

ACTA CYTOLOGICA

Illuminating Cellular Pathways for Future Discoveries
Publisher: KARGERISSN: 0001-5547Frequency: 6 issues/year

ACTA CYTOLOGICA is a premier journal dedicated to the field of cytology, offering a platform for researchers, professionals, and students interested in the intricate study of cellular biology and its applications in the medical domain. Published by KARGER in Switzerland, the journal has been a vital resource since its inception in 1960 and is recognized for its rigorous peer-reviewed articles. With a notable impact factor reflecting its significance—ranked in the Q2 category in both Medicine (miscellaneous) and Pathology and Forensic Medicine, and Q3 in Histology for 2023—ACTA CYTOLOGICA continues to contribute valuable insights into cytological research and its implications for clinical practice. The journal maintains an annual focus on cutting-edge studies and reviews that enhance understanding and methodological advancements in cytology. Although it does not provide open access, it remains an essential read for those involved in histology and pathology, promising to keep them abreast of the latest findings and technological innovations in the field.

Molecular Diagnosis & Therapy

Elevating Standards in Molecular Research
Publisher: ADIS INT LTDISSN: 1177-1062Frequency: 6 issues/year

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

Journal of Medical Imaging and Radiation Oncology

Exploring New Horizons in Medical Imaging and Radiation Therapy
Publisher: WILEYISSN: 1754-9477Frequency: 8 issues/year

Journal of Medical Imaging and Radiation Oncology, published by WILEY, is a pivotal resource in the fields of oncology and medical imaging. With an impact factor reflective of its commitment to advancing research, the journal has maintained a robust reputation since its inception in 2008 and continues to thrive through 2024. It is indexed with an insightful ranking, with a Q2 classification in Radiology, Nuclear Medicine and Imaging, affirming its importance in these disciplines. This journal not only serves as an open access platform, allowing extensive reach and accessibility, but also fosters a scholarly community dedicated to the innovation of imaging techniques and radiation oncology practices. As a key player in disseminating crucial findings and advancements, it appeals to researchers, clinicians, and students who aim to contribute to the evolving landscape of medical imaging and cancer treatment methodologies. The journal is based in Australia, at 111 River St, Hoboken, NJ, and invites submissions that push the boundaries of current knowledge in this critical area of healthcare.

Cancer Medicine

Unveiling the future of cancer therapies and treatments.
Publisher: WILEYISSN: 2045-7634Frequency: 12 issues/year

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

Journal of Cancer Research and Therapeutics

Elevating the dialogue in oncology and radiology.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0973-1482Frequency: 12 issues/year

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

Oncology Letters

Pioneering Research for a Brighter Future in Oncology
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

World Journal of Gastrointestinal Oncology

Advancing knowledge at the intersection of gastroenterology and oncology.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Journal of Cytology

Advancing Cytological Knowledge for a Healthier Tomorrow.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0970-9371Frequency: 4 issues/year

Journal of Cytology, published by Wolters Kluwer Medknow Publications, stands as a pivotal resource in the fields of cytology, histology, and pathology. With an ISSN of 0970-9371 and an E-ISSN of 0974-5165, this peer-reviewed, open-access journal has been disseminating vital research since its inception in 1985, transitioning to open access in 2008 to enhance global accessibility to its scholarly articles. Operating from its base in Mumbai, India, the journal is categorized in the Q3 quartile for histology and pathology according to the 2023 rankings, affirming its ongoing contribution to the scientific community. Researchers and professionals can benefit from a wide array of cutting-edge studies and reviews that advance the understanding of cytological practices. The journal's commitment to disseminating high-impact research is reflected in its Scopus rankings, positioning it among the significant players in its field. By facilitating open access, the Journal of Cytology aims to foster knowledge exchange and inspire new investigations among scholars, clinicians, and students alike.

CytoJournal

Pioneering Open Access to Transformative Medical Discoveries.
Publisher: SCIENTIFIC SCHOLAR LLCISSN: 0974-5963Frequency: 1 issue/year

CytoJournal is a leading open-access journal focused on the fields of pathology and forensic medicine, published by SCIENTIFIC SCHOLAR LLC. With its esteemed reputation, the journal has achieved a Q2 ranking in the 2023 Category Quartiles in its field, indicating its significant contribution and impact among its peers. Over its convergence from 2004 to 2024, CytoJournal has established itself as a pivotal platform for researchers, professionals, and students to disseminate and exchange pioneering research findings related to cytopathology and diagnostic techniques. With an emerging Scopus rank of #115 out of 208 in the field, the journal maintains a solid percentile ranking of 44th, underlining its importance in the scientific community. CytoJournal's commitment to facilitating open access ensures that critical insights and advancements in pathology and forensic medicine are easily accessible to those at the forefront of this essential area of study.

DIAGNOSTIC CYTOPATHOLOGY

Elevating Diagnostic Standards through Innovative Cytopathology
Publisher: WILEYISSN: 8755-1039Frequency: 12 issues/year

DIAGNOSTIC CYTOPATHOLOGY is a scholarly journal dedicated to advancing the field of cytopathology through the publication of high-quality research and reviews. Founded in 1985 and published by Wiley, this journal provides vital insights into the diagnosis and management of diseases through cytological techniques. With a strong presence in the academic community, it currently holds a Q3 ranking in the fields of Histology, Medicine (miscellaneous), and Pathology and Forensic Medicine, reflecting its commitment to fostering knowledge and innovation in these areas. Researchers and clinicians alike can benefit from its comprehensive articles that delve into cutting-edge methodologies and diagnostic strategies. Although not an Open Access journal, DIAGNOSTIC CYTOPATHOLOGY remains a crucial resource for professionals seeking to enhance their understanding and practice in the diagnostic realm. With an ISSN of 8755-1039 and an E-ISSN of 1097-0339, the journal continues to publish impactful studies well into 2024, ensuring that essential advancements in cytopathology reach a global audience.